# reload+after+2024-01-21 06:48:09.338132
address1§114 East 4th Avenue
address2§Suite 800
city§Vancouver
state§BC
zip§V5T 1G4
country§Canada
phone§604 678 1388
fax§604 737 7077
website§https://www.zymeworks.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, breast, colorectal, and endometrial cancers; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. It also develops a pipeline of preclinical product candidates and discovery-stage programs in oncology, including immuno-oncology agents and other therapeutic areas. Zymeworks Inc. has strategic partnerships and collaborations with BeiGene, Ltd.; Celgene Corporation; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; LEO Pharma A/S; Iconic Therapeutics, Inc.; Merck Sharp & Dohme Research GmbH; and Atreca, Inc. Zymeworks Inc. was incorporated in 2003 and is headquartered in Vancouver, Canada.
fullTimeEmployees§252
companyOfficers§[{'maxAge': 1, 'name': 'Mr. Kenneth H. Galbraith C.A.', 'age': 60, 'title': 'CEO & Chairman of the Board', 'yearBorn': 1963, 'fiscalYear': 2022, 'totalPay': 1224175, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Christopher  Astle Ph.D.', 'age': 43, 'title': 'Senior VP & CFO', 'yearBorn': 1980, 'fiscalYear': 2022, 'totalPay': 721233, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Bijal  Desai M.B.A.', 'title': 'Executive Director of Corporate Finance, FP&A & Procurement', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Mark  Hollywood', 'age': 53, 'title': 'Executive VP and Head of Technical & Manufacturing Operations', 'yearBorn': 1970, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Paul  Moore Ph.D.', 'age': 56, 'title': 'Chief Scientific Officer', 'yearBorn': 1967, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Jack W. Spinks', 'title': 'Associate Director of Investor Relations', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Daniel  Dex J.D., Ph.D.', 'title': 'Senior VP, Corporate Secretary & General Counsel', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Diana  Papove', 'title': 'Senior Manager of Corporate Communications', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': "Ms. Laura  O'Connor", 'title': 'Executive Director & Head of Global Human Resources', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Jeffrey  Smith M.D.', 'title': 'Senior Vice President of Early-Stage Development', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§8
boardRisk§8
compensationRisk§8
shareHolderRightsRisk§7
overallRisk§8
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§2
payoutRatio§0.0
beta§1.132
priceToSalesTrailing12Months§1.601505
currency§USD
dateShortInterest§1702598400
forwardEps§-1.18
pegRatio§-0.5
exchange§NMS
quoteType§EQUITY
shortName§Zymeworks Inc.
longName§Zymeworks Inc.
firstTradeDateEpochUtc§1493386200
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§73a7b41d-8e6f-3fa4-a390-f8202495de01
gmtOffSetMilliseconds§-18000000
targetHighPrice§19.0
targetLowPrice§8.0
targetMeanPrice§13.37
targetMedianPrice§12.5
recommendationMean§2.0
recommendationKey§buy
numberOfAnalystOpinions§10
quickRatio§4.979
grossMargins§0.63043
ebitdaMargins§0.45653
trailingPegRatio§None
